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From	pill	to	platform:	the	future	of	pharma	lies	beyond
illness
What	do	people	want	from	their	health	care?	A	new	pill?	Not	really…	What	they	really	want	is	to	live	long,	healthy
disability-free	lives,	and	then	die	fast	and	painlessly.	The	reason	that	what	people	get	is	different	from	what	they
need	lies	in	the	multiple	healthcare	challenges	we	face	at	the	moment,	including	but	not	limited	to	fragmented,
inflexible	health	systems,	inequity	of	access	and	outcome,	unsustainable	financing,	inability	to	adapt	to	ongoing
technology	development,	and	the	role	of	the	patient	as	passenger	rather	than	driver.
To	summarise	our	current	healthcare	status	in	one	sentence,	as	mentioned	by	Anne	Wojcicki,	23andMe	CEO:	‘it
seemed	wrong	that	no	one	made	money	if	we	stayed	healthy	but	lots	of	companies	would	make	money	if	we	got
sick…’
So	how	can	we	improve	healthcare?	How	do	we	create	a	new	patient-centred	and	fully-integrated	healthcare
ecosystem,	moving	away	from	yesterday’s	fragmented	and	volume-based	system	to	a	value-based	model?
Potentially,	we	can	address	the	challenges	through	partnerships,	through	digital	innovation,	increasing	patient
responsibility,	pushing	for	greater	effectiveness	(rather	than	efficiency	alone)	and	improved	combination	of	public
and	private	health	systems	together.	A	high	priority	is	to	redefine	industry	boundaries	and	business	models,	as	well
as	to	interweave	technology,	healthcare,	socioeconomics	and	leadership	evolutions	into	a	new	shape	for
healthcare.
Figure	1.	The	new	health	industry	ecosystem	and	“ways	to	play”
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Source:	Author’s	adaptation	from	The	new	health	industry	ecosystem	–	What’s	your	“way	to	play?,	in	strategy&,	PwC.	Royalty-free
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A	recent	phenomenon	is	the	case	of	companies	across	all	industries	transitioning	from	product-based	to	platform-
based	business	models,	as	has	been	adopted	by	the	pharmaceutical	industry	with	the	number	of	so-called	“pill	to
platform”	publications	growing	each	year	accordingly.
Several	companies	have	successfully	made	giant	leaps	and	transitioned	to	a	platform	based	models	already:
Ford	went	from	an	automaker	to	a	platform	company	delivering	mobility
Lego	shifted	from	a	toymaker	to	a	platform	for	learning	through	play
Sberbank	evolved	from	a	bank	to	a	do-it-all	tech	platform.
In	addition,	we	have	a	set	of	new	technologies,	or	rather	new	applications	of	existing	technology,	that	have	over	the
past	five	years	radically	improved	the	efficiency	of	some	industries:	the	world’s	largest	taxi	firm,	Uber,	owns	no	car;
the	world’s	most	popular	media	company,	Facebook,	creates	no	content;	and	the	world’s	most	valuable	retailer,
Alibaba,	carries	no	stock.	Something	big	is	going	on	and	it	is	obvious	that	the	healthcare	industry’s	time	has	come
(see	Figure	1,	above).
Healthcare	designed	around	us
Ground-breaking	digital	technology	and	the	convergence	of	escalating	priorities	and	unmet	needs	in	wellness	(eg,
nutrition,	weight	management,	physical	activity,	managing	and	sharing	personal	health	data	and	consumer-
genomics),	medical	(chronic	respiratory	disease,	telemedicine,	diabetes,	cardiovascular	disease	and	cancer)	and
consumer	(digital/mobile,	personalised,	social	media,	customer	support,	reminders	and	education)	categories	in
healthcare	are	transforming	the	landscape,	and	radically	redefining	the	possibilities	of	tomorrow.
As	a	result,	healthcare	will	be	designed	around	us:	patient-centred,	with	wearables	at	the	forefront,	digitised	and
with	decentralised	doctors	and	evolved	healthcare	provision.
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The	pharmaceutical	industry	is	moving	from	a	traditional	“pill”	model	to	a	“platform”	(pill	+	service	+	data	+	software)
model	to	deliver	value	beyond	treating	illness	and	to	start	facilitating	wellness.	By	establishing	fully	integrated,
partner-based	patient-centred	ecosystems,	companies	are	contributing	to	disease	prevention,	risk	awareness,	post-
treatment	and	wellness.
But	this	goes	beyond	the	classic	diagnostic	and	treatment	interventions,	instead	seizing	the	unique	opportunity
through	an	innovative,	well-coordinated	and	implementable	set	of	actions	that	bring	together	the	expertise,	support
and	collaboration	of	diverse	stakeholders.	In	other	words,	to	see	patient	wellness	and	illness	as	interconnected
elements	within	a	dynamic	equilibrium	–	helping	people	stay	well	and	live	fully,	as	well	as	manage	disease.
The	goalposts	are	moving.	Extending	a	patient’s	life	by	months	through	incremental	improvement	in	therapy	may
become	a	less	enticing	goal	in	the	future.	The	death	sentence	that	the	term	‘terminal	illness’	brings	may	not	be	seen
as	so	definitive.
Reimagining	patient	experiences
In	this	transformational	journey,	our	emerging	markets	team	decided	to	follow	an	unusual	and,	based	on	lessons
learned	during	the	implementation	phase,	challenging	direction:	to	create	and	strengthen	partnerships	that
accelerate	innovation,	increase	access	to	healthcare	and	improve	outcomes	for	society	using	the	concept	of	‘health
innovation	hubs’.
We	constructed	a	network	of	both	physical	locations	and	virtual	partnerships	that	work	to	solve,	scale	and
showcase	innovative	and	holistic	health	solutions	around	the	full	end-to-end	patient	journey	–	a	key	step	forward	in
our	commitment	to	delivering	truly	patient-centric	disease	management.
These	innovation	clusters	of	expertise,	ambition,	partnership	and	investment	around	digital,	R&D	and	academia
helps	us	reimagine	how	we	can	improve	patient	outcomes.	And,	vitally,	to	deliver	it.
Another	critical	pillar	to	enable	our	transition	to	a	platform	company	is	the	way	we	engage	patients,	which	needs	to
be	radically	transformed.	Patient	engagement	is	not	just	patient	communication	or	education	–	nor	is	it	simply
implementing	online	patient	portals,	but	active	collaboration	to	design,	manage	and	achieve	positive	outcomes
together.
Fundamentally	we	believe	that	the	pharmaceutical	industry	shares	a	collective	responsibility	with	healthcare
providers,	regulators,	governments,	payers,	civil	society,	entrepreneurs	and	other	stakeholders	to	work	together
and	enable	as	many	patients	as	possible	to	access	innovative	healthcare	solutions.
The	pharma	industry	are	uniquely	placed	to	leverage	our	scientific	expertise,	tools	and	capabilities	to	shape
medical	practice,	elevating	the	healthcare	environment	and	accelerating	innovation.	We	aspire	to	readdress	patient
experiences	and	help	people	to	live	long	healthy	disability-free	lives.	This	is	more	impactful	than	a	new	a	pill	only!
♣♣♣
Notes:
This	blog	post	expresses	the	views	of	its	author(s),	not	the	position	of	LSE	Business	Review	or	the	London
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Featured	image	by	CDC	on	Unsplash
When	you	leave	a	comment,	you’re	agreeing	to	our	Comment	Policy
Alexander	Bedenkov	(MD,	PhD)	is	vice	president	–	medical,	international	region	at	AstraZeneca.
	
	
	
LSE Business Review: From pill to platform: the future of pharma lies beyond illness Page 3 of 4
	
	
Date originally posted: 2020-10-22
Permalink: https://blogs.lse.ac.uk/businessreview/2020/10/22/from-pill-to-platform-the-future-1-of-pharma-lies-beyond-illness/
Blog homepage: https://blogs.lse.ac.uk/businessreview/
Andrey	Ipatov	(MD)	is	the	scientific	partnering	and	alliances	director,	international	region,	at
AstraZeneca.
	
	
	
Ryan	James	Bate	is	head	of	medical	strategy	and	project	management,	international	region,
AstraZeneca.
	
	
	
	
	
LSE Business Review: From pill to platform: the future of pharma lies beyond illness Page 4 of 4
	
	
Date originally posted: 2020-10-22
Permalink: https://blogs.lse.ac.uk/businessreview/2020/10/22/from-pill-to-platform-the-future-1-of-pharma-lies-beyond-illness/
Blog homepage: https://blogs.lse.ac.uk/businessreview/
